Acceptance of Intanza® 9 μg intradermal influenza vaccine in routine clinical practice in Australia and Argentina

摘要

Introduction Intanza® 9 μg (Sanofi Pasteur SA, Lyon, France), a split virion trivalent influenza vaccine delivered by intradermal injection with a microinjection system, became available as a vaccination for adults aged 18 to 59 years old, as of the 2010 southern hemisphere influenza season.